Table 2.

Clinical benefit and progression-free survival: multivariate analyses in patients with molecular alterations

Clinical Benefit (CR + PR + SD ≥ 6 months), evaluable for response (N = 1256)
Risk Factor (vs. other)	OR	95% CI	p
PI3K/AKT/mTOR alterations	.73	.53–1.02	.06
Liver metastases	.54	.39–.76	< .001
LDH > ULN	.61	.43–.86	.004
Performance status > 1	.50	.24–1.02	.06
Albumin < ULN	.68	.37–1.25	.21
Type of therapy added
Non-matched therapy	.67	.49–.90	.01
PI3K/AKT/mTOR alterations	.67	.48–.94	.02
Liver metastases	.55	.39–.77	< .001
LDH > ULN	.63	.45–.89	.01
Performance status > 1	.51	.25–1.05	.07
Albumin < ULN	.69	.97–1.27	.23
Progression-Free Survival (n = 1307)
Risk Factor (vs. other)	HR	95% CI	p
PI3K/AKT/mTOR alterations	1.11	.98–1.27	.09
Liver metastases	1.45	1.27–1.64	< .001
LDH > ULN	1.50	1.31–1.70	< .001
Performance status > 1	1.57	1.24–1.99	< .001
Albumin < ULN	1.35	1.09–1.67	.01
Platelets > ULN	1.14	.85–1.53	.39
Age ≥ 60 years	.97	.86–1.09	.57
Type of therapy added
Non-matched therapy	1.39	1.23–1.58	< .001
PI3K/AKT/mTOR alterations	1.16	1.02–1.32	.02
Liver metastases	1.43	1.26–1.62	< .001
LDH > ULN	1.44	1.26–1.64	< .001
Performance status > 1	1.54	1.22–1.95	< .001
Albumin < ULN	1.31	1.06–1.62	.01
Platelet count > ULN	1.09	.81–1.46	.59
Age ≥ 60 years	.95	.84–1.07	.37

Abbreviations: CI confidence interval, CR complete response, HR hazard ratio, LDH lactate dehydrogenase, PR partial response, SD stable disease, ULN upper limit of normal